Atrix, Sanofi sales and marketing update

SNY launched in the U.S. ATRX’s Eligard 22.5 mg three-month leuprolide luteinizing hormone-releasing hormone agonist depot to treat advanced prostate cancer. SNY already markets a one-month formulat...